Xicheng Sun, Ph.D. Vice President, Chemistry & Manufacturing at Crestone In. Prior to his current appointment, Dr Sun was an executive director of chemistry and CFTR modulator team leader at N30 Pharmaceuticals, overseeing internal and external activities from medicinal chemistry, chemical process development, and manufacturing of multi-kilo scale active pharmaceutical ingredients under cGMP, to compound screening using enzyme and cell-based assays and selection of candidate compounds for development. Prior to this appointment, he was a Principal Scientist at Replidyne, Inc. where he was responsible for discovering novel antibacterial agents against several biological targets, including methionyl-tRNA synthetase and bacterial DNA polymerases.
Dr. Sun is an author or co-author of more than 70 scientific papers, meeting proceedings and conference presentations, and an inventor or lead inventor of 34 issued patents, including the discovery of Telaprevir (INCIVEK), a HCV protease inhibitor approved for the treatment of HCV infection in 2011 and a number of drug candidates in clinical development: 1) CRS3123, a methionyl-tRNA synthetase inhibitor currently in Phase II clinical trials for the treatment of CDI; 2) N6022, a S-nitrosoglutathione reductase (GSNOR) inhibitor for the treatment of acute asthma and cystic fibrosis; 3) Cavosonstat (N91115), an oral GSNOR inhibitor currently in Phase II clinical trials for the treatment of COPD and asthma; 4) CRS0540, an orally bioavailable bacterial DNA polymerase inhibitor for Gram-positive bacterial infections in preclinical development; 5) CRS0393, a mmpL3 inhibitor for mycobacterial infections in preclinical development. Dr. Sun received his BS, MS, and Ph.D. degrees in chemistry from the Dalian University of Technology in Dalian, China and conducted his post-doctoral research at the Swiss Federal Institute of Technology (ETH) in Zürich and University of Lausanne, Switzerland.